A. Klaiber

Development and validation of an LC-MS/MS method for the quantification of mescaline and major metabolites in human plasma.

M. Liechti, U. Duthaler, L. Ley, 2022, Journal of pharmaceutical and biomedical analysis.

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

M. Liechti, U. Duthaler, A. Eckert, 2022, The international journal of neuropsychopharmacology.

Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double‐Blind, Placebo‐Controlled, Crossover Study in Healthy Subjects

M. Liechti, E. Grünblatt, U. Duthaler, 2021, Clinical pharmacology and therapeutics.

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

M. Liechti, D. Luethi, U. Duthaler, 2023, Neuropsychopharmacology.

Acute effects of MDMA and LSD co-administration in a double-blind placebo-controlled study in healthy participants

M. Liechti, U. Duthaler, A. Eckert, 2023, Neuropsychopharmacology.

Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants

M. Liechti, D. Luethi, U. Duthaler, 2023, Translational psychiatry.

The association between real-life markers of phone use and cognitive performance, health-related quality of life and sleep.

M. Eeftens, M. Röösli, J. Wiart, 2023, Environmental research.